Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

U.S. stock indexes inched their way to more records Monday to kick off a week full of profit updates from big U.S. companies.

U.S. stock indexes inched their way to more records on Monday to kick off a week full of profit updates from big U.S.

U.S. stock indexes inched to more records to kick off a week full of profit updates from big U.S. companies. The S&P 500 rose ...

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock plummet in premarket trading Friday following the disclosure of a patient ...

On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died.